Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, announced on Thursday that it has signed a five-year supply agreement with AdvanCell, an Australian radiopharmaceutical company, to deliver Thorium-228.
The deal, valued at approximately NOK100m, follows successful deliveries of Thorium-228 samples from Thor Medical's new pilot facilities to AdvanCell earlier this year.
AdvanCell will use the Thorium-228 to produce Pb-212, a key ingredient in its cancer therapies, including ADVC001, which is currently in Phase I/II clinical trials.
This is Thor Medical's third commercial supply agreement this year.
Vivesto strengthens Cantrixil programme with positive preclinical data
Thor Medical signs supply deal with AdvanCell
Abilita and Orion partner on antibody therapeutics for oncology and pain
Breckenridge Pharmaceutical launches FDA approved methadone injection
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Guardant Health and Boehringer Ingelheim partner on lung cancer diagnostic
Mendus reports positive topline data from ovarian cancer trial
Fosun International receives Outstanding ESG Award
Samsung Biologics invests in Generate:Biomedicines
SK Biopharmaceuticals agrees research collaboration with ProEn Therapeutics